LVTX LAVA Therapeutics NV revenue, earnings and financials
For the quarter ended September 30, 2025, LAVA Therapeutics NV reported revenue of n/a, net income of −$7.19M and diluted EPS of −$0.27; for the fiscal year ended December 2024 revenue was $12.0M, up 77.0% on the year before.
LVTX annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $12.0M, gross profit n/a, operating income −$29.7M, net income −$25.1M (margin -209.6%), EPS −$0.94
- Fiscal year ended Dec 2023: revenue $6.77M, gross profit n/a, operating income −$43.4M, net income −$41.9M (margin -618.6%), EPS −$1.57
LVTX quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue n/a, net income −$7.19M, EPS −$0.27
- Quarter ended Jun 30, 2025: revenue n/a, net income −$8.64M, EPS −$0.32
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.48M, EPS −$0.13
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$3.88M, EPS −$0.15
- Quarter ended Sep 30, 2024: revenue n/a, net income −$12.3M, EPS −$0.46
- Quarter ended Jun 30, 2024: revenue n/a, net income −$8.30M, EPS −$0.31
- Quarter ended Mar 31, 2024: revenue $6.99M, net income −$608K, EPS −$0.02
LVTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$19.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$40.3M, share buybacks n/a
LVTX balance sheet
- Sep 30, 2025: cash $49.7M, total assets $51.9M, total liabilities $39.2M, shareholders' equity $12.7M
- Jun 30, 2025: cash $26.4M, total assets $60.5M, total liabilities $40.6M, shareholders' equity $19.9M
- Mar 31, 2025: cash $39.7M, total assets $71.2M, total liabilities $45.4M, shareholders' equity $25.8M
- Dec 31, 2024: cash $35.0M, total assets $80.8M, total liabilities $53.1M, shareholders' equity $27.7M
- Dec 31, 2023: cash $44.2M, total assets $102M, total liabilities $50.3M, shareholders' equity $51.4M
What is LVTX's revenue?
LAVA Therapeutics NV reported $12.0M of revenue for the fiscal year ended December 2024.
Is LVTX profitable?
No. LAVA Therapeutics NV lost $23.2M over the last four quarters.
What is LVTX's EPS?
Diluted earnings per share over the last four quarters were −$0.87; −$0.27 in the latest quarter.